These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 21954818)
21. Targeted therapies: a new generation of cancer treatments. Gerber DE Am Fam Physician; 2008 Feb; 77(3):311-9. PubMed ID: 18297955 [TBL] [Abstract][Full Text] [Related]
22. Targeting the vascular endothelial growth factor pathway in the treatment of human malignancy. Tonra JR; Hicklin DJ Immunol Invest; 2007; 36(1):3-23. PubMed ID: 17190647 [TBL] [Abstract][Full Text] [Related]
31. Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: understanding and managing a new syndrome. Small HY; Montezano AC; Rios FJ; Savoia C; Touyz RM Can J Cardiol; 2014 May; 30(5):534-43. PubMed ID: 24786444 [TBL] [Abstract][Full Text] [Related]
32. Molecular mechanisms of hypertension and heart failure due to antiangiogenic cancer therapies. Rees ML; Khakoo AY Heart Fail Clin; 2011 Jul; 7(3):299-311. PubMed ID: 21749882 [TBL] [Abstract][Full Text] [Related]
33. [Nephrotoxicity--proteinuria and hypertension--]. Ando M Gan To Kagaku Ryoho; 2008 Oct; 35(10):1649-53. PubMed ID: 18931564 [TBL] [Abstract][Full Text] [Related]
34. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors. Eskens FA; Steeghs N; Verweij J; Bloem JL; Christensen O; van Doorn L; Ouwerkerk J; de Jonge MJ; Nortier JW; Kraetzschmar J; Rajagopalan P; Gelderblom H J Clin Oncol; 2009 Sep; 27(25):4169-76. PubMed ID: 19636022 [TBL] [Abstract][Full Text] [Related]
35. Angiogenesis inhibitors in the treatment of lung cancer. Sun S; Schiller JH Crit Rev Oncol Hematol; 2007 May; 62(2):93-104. PubMed ID: 17306557 [TBL] [Abstract][Full Text] [Related]